Discovery and Development of New Biologics and Biosimilars
Prestige BioPharma’s focal point is on the discovery and development of innovative new biologics and biosimilars. The first biosimilar, HD201 Trastuzumab is currently in global Phase III clinical trial and projected market launch in 2019.
A frontier in Biopharmaceuticals
Prestige BioPharma focuses on biosimilars and new antibody therapeutics with solid foundation in APAC regions and rapidly advances to be a strong player and frontier in the global biopharmaceutical market.
Creating Differences &
Value for Human Health
Prestige BioPharma strives to improve accessibility and affordability for existing biologic drugs and research on unmet medical needs to provide cure for devastating diseases.
Innovation for Life
Prestige Biopharma thrives to become one of the top biopharmaceuticals specializing in discovery of new biologics and next series of biosimilars through its solid and innovative technology platform.
A series of biosimilar drugs are currently under advanced clinical and nonclinical development stages. Based on the technology and capabilities established from the successful development of these biosimilars, the next tier of biosimilars and new antibody therapeutics are under development.